TNFRSF8 and mycosis fungoides: The FDA granted regular approval of BV on 9 November 2017 for the treatment of CD30-expressing mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL), for patients who have received prior systemic therapy [56].